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ABSTRACT
HARDINESS AND ITS RELATIONSHIP TO 
ANTICIPATORY NAUSEA AND VOMITING EXPERIENCED 
BY THE PATIENT RECEIVING CISPLATIN CHEMOTHERAPY
By
Colleen K. Smith 
Research suggests that the hardiness characteristic 
acts as a buffer in the stress/illness relationship.
The purpose of this study was to assess the presence of 
hardiness and examine its relationship to the amount of 
anticipatory nausea and vomiting experienced within a 
sample of patients receiving cisplatin chemotherapy.
It was hypothesized that individuals with a high level of 
hardiness would experience less anticipatory nausea and 
vomiting than individuals with a low level of hardiness.
A prospective descriptive correlational design was 
utilized. A convenience sample of adults with cancer 
(n=29) receiving cisplatin intravenously was studied. All 
patients were assessed via two measurement tools: the
Health Related Hardiness Scale (Pollock, 1984) and the 
Rhodes Index of Nausea and Vomiting Form 2 (Rhodes,
Watson, Johnson, Madsen, & Beck, 1987). The hypothesis 
was not supported as being statistically significant, 
however, there was a greater tendency for those who were 
hardy to experience less anticipatory nausea and vomiting.
ii
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CHAPTER ONE 
INTRODUCTION
Oncology patients provide a multitude of diverse 
challenges for the health care practitioner. Many of 
these challenges arise from the illness trajectory 
induced by the cancer itself, while others arise from 
the treatment regime employed to combat the cancer. One 
identified treatment induced challenge is that of 
anticipatory nausea and vomiting associated with 
chemotherapy.
Many patients receiving the same or similar 
chemotherapeutic drugs experience wide differences in 
side effects. Nausea and vomiting have long been 
identified as two of the most frequently experienced 
side effects of chemotherapy. This includes nausea and 
vomiting that result from the anticipation of treatment. 
As with other chemotherapy side effects, a wide range in 
the frequency, intensity, and duration of anticipatory 
nausea and vomiting can be observed from patient to 
patient.
Research to date has not provided definitive 
answers to explain why one individual tolerates a 
particular chemotherapeutic agent better than another
individual receiving the same drug. Nursing recognizes 
one of its goals as offering competent individualized 
care to clients and, therefore, must delve into issues 
that may explain why each individual responds 
differently. By identifying factors that influence 
individual responses, interventions that support 
individualized nursing care can be identified.
One factor that requires further exploration is 
that of hardiness. Kobasa (1979) initially identified 
hardiness as a personality characteristic that may act 
as a buffer, or resistance factor, in preventing 
illness. Anticipatory nausea and vomiting result as 
undesirable responses to chemotherapy. If the 
hardiness characteristic does act as a resistance factor 
to prevent the development of anticipatory nausea and 
vomiting, it is essential that further research explore 
this quality. Identification of such resistance factors 
may aid patients in the management and reduction of 
anticipatory nausea and vomiting due to chemotherapy.
The purpose of this study was to assess the presence 
of the hardiness characteristic and examine its 
relationship to the amount of anticipatory nausea and 
vomiting experienced within a sample of patients 
receiving cisplatin as their primary chemotherapeutic 
agent. Knowledge of this relationship may facilitate
the identification and utilization of psycho- 
physiological nursing interventions to assist the cancer 
patient experiencing anticipatory nausea and vomiting.
CHAPTER TWO 
LITERATURE AND THEORY
Literature Review
Advances in cancer therapy have provided reason for 
hope and actual cure in many patients. Chemotherapy is 
a modality of treatment for cancer that offers improved 
outcomes, but in addition, a multitude of side effects. 
These side effects can affect not only the quality of 
life for the cancer patient, but also the compliance 
with the individual treatment regime. Anticipatory 
nausea and vomiting is one such undesirable side effect 
that can influence the patient's compliance with cancer 
therapy.
The development of anticipatory nausea and vomiting 
has been identified in terms of classical conditioning. 
Pratt, Lazar, Penman, and Holland (1984) describe this 
process. The chemotherapeutic agent, identified as the 
unconditioned stimulus, produces an unconditioned 
reflexive response, nausea and/or vomiting. If 
extraneous factors, such as odors or surroundings, 
become paired with the unconditioned stimulus, these 
previously innocuous stimuli then become conditioned 
stimuli. The responses which result from conditioned
stimuli are identified then as conditioned responses. 
Therefore, when the patient receiving chemotherapy 
experiences nausea and vomiting, often neutral 
stimuli become paired with the chemotherapy induced 
nausea and vomiting. After repeated experiences, the 
patient experiences nausea and may vomit when simply 
exposed to the neutral stimuli.
Nerenz, Leventhal, Easterling, and Love (1986) 
present a conditioned anxiety model to explain the 
development of anticipatory nausea and vomiting. This 
model identifies anticipatory nausea and vomiting as the 
result of an emotional state or aversion that is a 
conditioned response to external stimuli. Interview 
data obtained from 192 patients receiving chemotherapy 
for the first time was analyzed to identify predictive 
factors for the development of anticipatory nausea and 
vomiting. Three predictors were identified; post­
treatment nausea and vomiting, tastes of drugs during 
injections, and anxiety before injections. Although 
this study was limited due to the use of retrospective 
interview methodology and a broad definition of 
anticipatory nausea and vomiting, evidence was elicited 
to suggest that anxiety resulting from post-treatment 
nausea and vomiting did facilitate the later development 
of anticipatory nausea and vomiting.
Goodman (1987) states that as a result of post- 
chemotherapy nausea and vomiting, particularly with 
cisplatin as the primary chemotherapeutic agent, 
effective antiemetics must be utilized. If inadequate 
antiemetic therapy is used, fear and anxiety result.
This fear and anxiety subsequently become the 
conditioned response to chemotherapy and anticipatory 
nausea and vomiting are more likely to result.
The reported prevalence and related influencing 
variables of anticipatory nausea and vomiting have 
varied in the research to date. Morrow (1982) reported 
twenty-one percent (47 of 225 patients) as having 
experienced anticipatory nausea and vomiting prior to a 
chemotherapy treatment. Examination of demographic and 
clinical factors determined that patients with 
c nticipatory nausea and vomiting experienced severe 
post-treatment vomiting, experienced severe nausea after 
treatment, and were more likely to be receiving cisplatin 
than patients without anticipatory side effects.
Reporting an incidence of one in four patients who 
experience anticipatory nausea and vomiting by the time 
of their fourth treatment. Morrow (1984) conducted a 
study to identify characteristics of patients at a high 
risk for developing anticipatory nausea and vomiting.
The identified characteristics were:
(1) less than 50 years of age; (2) the experience 
of nausea and/or vomiting after their last 
chemotherapy treatment; (3) a description of nausea 
after the last treatment as "moderate, severe, or 
intolerable"; (4) a description of vomiting after 
the last treatment as "moderate, severe, or 
intolerable"; (5) the reporting of the side effect 
"warm or hot all over" after their last treatment;
(6) a susceptibility to motion sickness; (7) the 
experience of "sweating after the last treatment";
(8) and the experience of "generalized weakness 
after the last chemotherapy treatment" (p. 1170). 
Patients who experienced anticipatory nausea and 
vomiting were significantly more likely (p<.001 using the 
Chi-square test) to have four or more of these 
characteristics.
Coons, Leventhal, Nerenz, Love, and Larson (1987) 
studied thirty-four patients receiving cisplatin-based 
chemotherapy. This study was conducted to determine the 
percentage of patients who experienced anticipatory 
nausea, to assess factors associated with the development 
of anticipatory nausea, and to examine the affect of 
anticipatory nausea on emotional distress with treatment. 
All subjects experienced post-treatment nausea and/or
vomiting. Anticipatory nausea was experienced by sixty- 
five percent of the sample in one or more situations. 
Patients who experienced any anxiety during their first 
injection reported a somewhat higher frequency of 
anticipatory nausea than those who were not anxious, 
however, the study failed to achieve statistical 
significance in this relationship. This was due primarily 
to the limitation of a small sample size.
Andrykowski et al. (1988) studied factors related 
to the prevalence, prediction, and course of 
anticipatory nausea in women (N=77) receiving adjuvant 
chemotherapy for breast cancer. Via a prospective 
longitudinal research design, patients were interviewed 
before and after each chemotherapy treatment. Findings 
indicated fifty-seven percent of the patients developed 
anticipatory nausea. Two important factors influencing 
this development were the severity and duration of post­
treatment nausea following the initial infusion and the 
patient's expectations for experiencing nausea. While 
the results of the study indicate that anxiety levels at 
the initial infusion were not associated with the future 
likelihood of developing anticipatory nausea, it was 
suggested that anxiety appears to contribute to the 
development of anticipatory nausea in patients who have 
not already developed it following the initial infusion.
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It is suggested that anticipatory nausea could be 
prevented or delayed through improved control of anxiety 
during the chemotherapy treatment course.
Stefanek, Sheidler, and Fetting (1988) assessed the 
prevalence of anticipatory nausea and vomiting in patients 
(N=121) who received intravenous chemotherapy over a 
seven week period. Ten percent (12) of the subjects 
received cisplatin-containing regimens. This study was 
conducted via cross-sectional prevalence methodology.
They reported a prevalence ratio of thirty-three percent, 
with the length of post-chemotherapy nausea as 
significantly related to the development of anticipatory 
symptoms. However, they identified that the severity of 
anticipatory symptoms was very mild to mild. This 
study concluded that anticipatory nausea and vomiting is 
not a significant clinical problem for a large majority of 
patients receiving chemotherapy, however, a significant 
minority of patients experience anticipatory symptoms.
In summation, a review of the research revealed 
several factors which have an impact on the development of 
anticipatory nausea and vomiting. Relevant factors were 
post-treatment nausea and vomiting, fear and anxiety 
that result from treatment, and the chemotherapeutic 
agent used for treatment.
cisplatin is recognized as a highly emetogenic drug, 
and the literature identifies highly emetogenic agents as 
contributing to the development of anticipatory nausea and 
vomiting (Briscoe, 1989; Coons, Leventhal, Nerenz, Love, & 
Larson, 1987; Clark, 1989; Duigon, 1986; & Hogan, 1990). 
While cisplatin has become an instrumental 
chemotherapeutic agent, its success has been influenced by 
the often times severe nausea and vomiting that occurs in 
most patients who receive this drug (Goodman, 1987).
Nausea and vomiting may be severe and often begin one to 
six hours after the administration of the drug and can 
persist up to twenty-four hours or longer (McEvoy, 1990). 
It becomes essential to intervene with the symptomatology 
of nausea and vomiting that result from this agent in an 
effort to increase patient comfort and compliance.
If nursing interventions are to be effective, an 
examination of all factors that have an impact on the 
development of anticipatory nausea and vomiting should 
occur. This includes an examination of factors that may 
buffer, thereby reduce, the untoward response identified 
as anticipatory nausea and vomiting. One factor that may 
act as a buffer is the personality factor hardiness.
A search of the relevant nursing and medical 
literature revealed no studies examining the individual 
hardiness characteristic specifically related to cancer or
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to the side effects resulting from therapy for cancer. 
Carey, Oberst, McCubbin, and Hughes (1991) utilized the 
concept of family hardiness in an exploratory study to 
examine appraisal and caregiving burden in family members 
caring for patients receving chemotherapy. Family 
hardiness was again examined in relationship to the 
appraisal of illness, symptom distress, self-care burden, 
and mood states in patients receiving chemotherapy for 
intial and recurrent cancer (Munkres, Oberst, and Hughes, 
1992). While these studies examined family hardiness, 
they do not address individual hardiness, the focus of 
this study. There were, however, a number of studies that 
explored the hardiness characteristic in relationship to 
stress, illness, and adaptation.
Kobasa (1979) utilized a retrospective descriptive 
correlational design to examine stressful life events, 
personality, and health. Two groups were refined from a 
large subject pool (N=827) that consisted of all middle 
and upper level executives of a large public utility.
The groups were divided based on the completion of a 
stress and illness questionnaire. Group one (N=86) 
consisted of executives who suffered high stress/low 
illness. Group two (N=75) consisted of executives who 
suffered high stress/high illness. These groups were 
then administered a composite of several personality
11
tests to evaluate personality characteristics (including 
hardiness) and their relationship to stress and health.
The findings, as they related to stress and illness, 
showed a weak, but significant correlation (r=.24, p<.025) 
between stress and illness. Kobasa did support her 
hypothesis that the high stress/low illness executives 
had a higher level of hardiness than the high 
stress/high illness executives. The limitations of this 
study included self-report measures for data collection 
and potential distortion of findings due to a variable 
identified as illness behavior; Subjects want to act and 
behave as if they are ill and thus report themselves as 
ill.
Pollock (1586) hypothesized that the presence of 
the hardiness characteristic would correlate with 
physiological adaptation in chronically ill adults.
A convenience sample (N=60) of male and female adults 
diagnosed with adult onset illness for at least one year 
was identified. The sample was divided into three equal 
groups based on diagnosis: insulin dependent diabetes
mellitus (N=20), essential hypertension (N=20), and 
rheumatoid arthritis (N=20). Physiological adaptation 
was measured via a scale specific to each of the three 
identified diagnoses. Hardiness was measured by the 
Health Related Hardiness Scale developed by Pollock in
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1984. Results of this study indicated that the presence 
of hardiness was related to adaptive behavior in the 
diabetic group, but not in the arthritic or hypertensive 
group. The small sample size in each diagnostic category 
was identified as a limitation in this study, along with 
the difficulty of examining common elements in these 
diagnostic categories without accounting for the 
differences between categories.
Schmied and Lawler (1986) used a correlational design 
to examine the relationships among stress, illness, 
hardiness, and Type A behavior in a convenience sample 
(N=82) of female secretaries. The findings indicated a 
strong positive relation between stress and illness with 
no relation between Type A behavior and illness 
(F(l,72)=3.67, p=.05). In addition, there were no 
hardiness effects or interactions between stress. Type A 
behavior, and hardiness. One of the primary limitations 
of this study is that one cannot generalize from the 
secretarial work force response to all working women, thus 
its application is limited.
Using a correlational design. Rich and Rich (1987) 
examined the burnout-moderating effects of the hardiness 
characteristic in female staff nurses. A convenience 
sample (N=100) of staff nurses was studied. This group of 
nurses had at least one year of experience as a staff
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nurse in an acute care hospital in western Pennsylvania. 
The results of this study supported the hypothesis that 
personality hardiness is an important stress-resistance 
attribute in preventing or reducing burnout in female 
staff nurses. The education level of the nurses in this 
study was obtained as a demographic variable, but was not 
discussed as a possible influence on burnout. Another 
limitation identified was that this sample was taken from 
only one hospital with no mention of benefits and/or work 
environment that may have influenced burnout in the 
sample.
Banks and Gannon (1988) conducted a prospective 
study to examine the potential of hardiness as a 
mediator in the relationship between stress and 
symptoms. Thirty male and fifty-eight female students 
received questionnaires on four separate occasions at 
one-month intervals. Results indicate that hardiness 
tended to have additive and opposite effects in looking 
at it as a mediator between stress and symptoms. Those 
with a higher hardiness level experienced stress less 
often and perceived minor events as less stressful. 
Limitations include the use of self-reported measures 
and a short prospective period of assessment.
In a survey of women with rheumatoid arthritis 
(N=122), Lambert, Lambert, Klipple, and Mewshaw (1989)
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explored the ability of social support and hardiness to 
predict psychological well-being. Subjects were 
administered three questionnaires via interviews, with 
results suggesting that both satisfaction with social 
supports and the presence of hardiness were factors that 
enhance coping with a chronic debilitating disease. 
Limitations of the study include the restricted usefulness 
of determining causal effects with the exploratory survey 
design, and the inability to generalize findings as the 
subjects were primarily Caucasian, well educated, and from 
a high socioeconomic background.
Ross (1991) conducted a study to determine if the 
presence of hardiness influenced compliance in elderly 
patients with diabetes (N=50). The Health Related 
Hardiness Scale (HRHS), developed by Pollock, was utilized 
to measure hardiness. The Self-Management Compliance 
Questionnaire was administered to measure compliance with 
the prescribed diabetic regime. The Pearson r correlation 
coefficient was calculated to demonstrate a significant 
relationship between the total HRHS score (r=-.60, p,.05) 
and compliance. The results of this study suggest that 
the degree of hardiness in individuals with diabetes may 
predict compliance to a prescribed diabetic regimen. A 
limitation to this study was the inability to generalize
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the findings as the subjects were primarily white, male, 
married, and diagnosed with Type II diabetes.
It is determined from these studies that there does 
exist a relationship between stress and illness and that 
hardiness may act as a mediator in the stress/illness 
link, however, more research is needed to support 
previous research and to further examine the hardiness 
characteristic and its relationship to both stress and 
illness.
Theoretical Framework
The development of anticipatory nausea and 
vomiting has been described in the literature via the 
classical conditioning model and the conditioned anxiety 
model. However, symptom development can also be 
approached from a stress theory framework. Few would 
dispute that cancer and its treatment are a source of 
anxiety and stress. Lindsey and Carrieri (1986) identify 
stress as a sociopsychophysiological phenomenon, therefore 
an interaction of physiologic, mental, and behavioral 
responses to a stressor of some type. Lindsey and 
Carrieri further identify stress as an integrated 
hypothalamic response that is subject to the strength of 
the stimulus (stressor) and is modified by specific 
individual characteristics such as age, sex, and previous 
experience. The stress response is identified as a
16
protective adaptive function (Lindsey & Carrieri, 1986) 
unless the stressor is prolonged or severe, in which 
case illness or maladaptation occurs.
The life stress and illness model (Rahe, 1988) 
identifies a series of steps to represent the sequence 
of events from exposure of a life stressor to the 
development of illness.
1. Life events may be altered based on an 
individual's perception of these events.
2. Psychological defense mechanisms can be 
utilized to buffer the impact of a life stressor, 
however, these defenses are not adaptive for extensive 
periods of time.
3. If a life stressor cannot be buffered, the 
stressor may persist to stimulate physiological 
reactions.
4. If an individual is aware of these 
psychophysiological responses, and the responses are 
perceived as a threat to health, they become symptoms.
5. When the individual's ability to cope is 
inadequate, and the symptoms become prolonged and 
severe, anxiety and illness result.
The life stress and illness model supports the 
relationship between stressor and symptom in the cancer 
patient receiving chemotherapy. The stressor may be
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identified as the chemotherapeutic agent administered to 
the patient. Often the agent produces nausea and 
vomiting post-treatment, which acts to reinforce the 
agent as a stressor. The psychophysiologic response to 
this stressor, if unbuffered, may result in the symptom 
of anticipatory nausea and vomiting.
It must be recognized that a number of factors 
interface to produce the individual's perception of the 
stressor. Often an individual's perception evolves from 
both life events and individual personality attributes. 
Kobasa (1979) proposed that people who experience high 
degrees of stress without falling ill may have a 
specific personality characteristic that differentiates 
them from people who do become sick under stress: 
hardiness is that characteristic. The hardiness 
characteristic, therefore, may well act as a buffer, or 
resistance factor, in the stress/illness connection.
The hardiness trait would affect an individual's 
perception of chemotherapy, thereby resulting in a 
greater resistance to the symptomatology of anticipatory 
nausea and vomiting that evolves from the stressor 
chemotherapy.
Existential psychology provides the basic framework 
for the development of the concept of hardiness as it is 
used in this study. Existential philosophy views the
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ultimate aim of life as the "creation of personal 
meaning through decision making and action in the 
continual pursuit of possibility" (Bigbee, 1985, p. 54). 
The existential viewpoint (Bigbee, 1985) considers 
stressful life events as a challenge that enables an 
individual to grow and pursue a higher level of 
authenticity.
From this overview of existential philosophy, the 
three basic components of the hardiness characteristic 
evolve (Kobasa, 1979). These three components are 
identified as control, commitment, and challenge.
Control is determined according to the individual's 
locus of control: internal or external. Internally
oriented people are able to face stressors by believing 
they can modify the stressor as a result of their own 
efforts or attributes, while externally oriented people 
believe they have little to no control over events in 
their lives. Hardy individuals have an internal locus 
of control. Commitment is identified in the hardy 
individual as a purpose in life which is supported by a 
strong sense of dedication to personal values, beliefs, 
and to self. Committed individuals have a belief system 
that acts to decrease the perception of life events as 
threatening. Lastly, challenge is perceived by the 
hardy person as an opportunity for growth (Kobasa,
19
1979) . Stress and change are therefore viewed as
potential growth experiences.
Definition of Terms
The key concepts identified for this study were:
A. Hardiness: a specific personality characteristic 
which acts as a resistance factor in the stress- 
illness connection. The hardiness characteristic is 
a composite of three other traits identified as 
control, commitment, and challenge (Kobasa, 1979).
B. Control: the belief that one can influence or 
direct the events in their life (Kobasa, 1979).
C. Commitment: the ability to believe in the
importance of and feel deeply involved in the 
activities of one's life (Kobasa, 1979).
D. Challenge; the belief that change is a normal part 
of life and an incentive for growth rather than a 
threat to growth (Kobasa, 1979).
E. Perception: the process of evaluating stimuli
as threatening or nonthreatening.
F. Anticipatory nausea: the patient's perception of
feeling sickness at the stomach that occurs twenty-
four hours prior to, in expectation of, chemotherapy.
G. Anticipatory vomiting: the patient's perception of
the expulsion of stomach contents (emesis) that
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occurs twenty-four hours prior to, in expectation 
o f, chemotherapy.
H. Chemotherapy: the use of chemical pharmacologic
agents in the treatment of cancer.
As a result of examining anticipatory nausea and 
vomiting as symptoms resulting within the stress and 
illness framework, factors which mediate this response 
must be examined. Therefore, the following research 
question was posed: What is the relationship of the
hardiness characteristic to anticipatory nausea and 
vomiting experienced by the patient receiving cisplatin 
chemotherapy?
The conceptual framework of the research question 
is diagramed below (see Figure 1):
rControl 
Hardiness—4 Commitment 
I _ '-Challenge 
I 
I
I -N.
Stressor--------- Perception--------- Anticipatory Nausea
(Chemotherapy) and Vomiting
Figure 1. Model of Conceptual Framework 
Hypothesis
The resultant hypothesis was identified as: 
Individuals with a high level of the hardiness 
characteristic (control, commitment, and challenge) will 
experience less anticipatory nausea and/or vomiting than
21
those individuals with a low level of the hardiness 
characteristic.
22
CHAPTER THREE 
Methodology
Research Design
The purpose of this study was to describe the 
relationship between the hardiness characteristic and 
anticipatory nausea and vomiting experienced by patients 
receiving chemotherapy. A prospective descriptive 
correlational design was used.
Sample and Setting
The source of subjects for this study was oncology 
patients who received chemotherapy on an in-patient basis 
at a 529-bed metropolitan regional hospital, a 190-bed 
community hospital, a 350-bed regional hospital, and a 
405-bed regional hospital, all of which were located in 
the Midwest. A convenience sample of 40 subjects was 
utilized for this study. The sample consisted of men and 
women with a confirmed diagnosis of cancer. The subjects 
all received cisplatin, at least 70 mg/m2, as one of their 
primary chemotherapeutic agents. The subjects were 
between cycle two and six of their chemotherapy protocol. 
In addition, the subjects were between the ages of 18-79, 
alert and oriented to person, place, and time, and able to 
read and write English.
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Patients were excluded from this study if they had 
a confirmed primary gastrointestinal cancer or were 
receiving radiation therapy to the upper and lower 
abdomen.
Instruments
There were two major instruments for data 
collection used in this study: the Health Related
Hardiness Scale (HRHS) and the Rhodes Index of Nausea 
and Vomiting Form 2 (INV Form 2). In addition, a 
demographic and related data form was utilized to 
obtain information about the subjects via interview 
(Appendix A), a chart review form was utilized to 
obtain information relevant to the chemotherapy protocols 
the patient had received and was to receive (Appendix 
B), and a patient questionnaire was utilized to obtain 
information about how the patient felt after 
chemotherapy (Appendix C).
In early studies aimed at measuring the hardiness 
characteristic, Kobasa's Hardiness Scale (Kobasa, 1979) 
was widely used. The Health Related Hardiness Scale 
(Pollock, 1986) is a more recent instrument developed to 
better measure the hardiness characteristic in 
individuals with an actual or potential health problem 
(Appendix D). The HRHS contains 40 items rated on a 6- 
point, forced-point scale from strongly disagree to
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strongly agree. There are three subscales for 
control, commitment, and challenge. The 14 items to 
measure control were selected from the Multidimentional 
Health Locus of Control Scale, while items to measure 
the commitment and challenge concepts were developed 
from operational definitions of commitment to health 
related activities and motivation for health promotion.
Content validity of the HRHS was addressed by 
Pollock (1989) by asking a panel of judges (faculty and 
doctoral students with experience in adult health) to 
evaluate the representativeness of the control, 
commitment, and challenge items. Interrater reliability 
was .85 via interclass correlation of raters, thus 
assuring selection of the best items to measure the 
three concepts. This same panel evaluated both the HRHS 
and Kobasa's Hardiness Scale (Kobasa, 1979) for 
measuring the hardiness characteristic, with experts all 
agreeing that the HRHS was the more appropriate 
instrument (Pollock, 1989).
Internal consistency of the HRHS was established 
via a pilot study (N=65 well adults) in which the 
subjects completed both Kobasa's Hardiness Scale and the 
HRHS. The HRHS indicated better reliability (higher 
alpha coefficients) as compared to Kobasa's scale.
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Table 1 below illustrates the alpha coefficients obtained 
from each test.
Table 1
Comparison of Alpha Coefficients from HRHS and Kobasa's 
Hardiness Scale
HRHS Kobasa's Scale 
Total instrument; .80 .65
Control subscale: .82 .55
Commitment subscale: .74 .58
Challenge subscale: .65 .23
Internal consistency reliabilities using Cronbach's 
alpha for the 40-item HRHS for this study were .70 for the 
total score, .65 for the control subscale, .48 for the 
commitment subscale, and .26 for the challenge subscale.
The Rhodes Index of Nausea and Vomiting Fomn 2 
(Rhodes, Watson, Johnson, Madsen, & Beck, 1987) was 
utilized to measure anticipatory nausea and vomiting.
The INV Form 2 is an 8-item, 5-point, Likert-type scale, 
utilized in a self-report method (Appendix D). The INV 
Form 2 was designed to measure nausea and vomiting in the 
subject in 12 hour blocks of time after the subject had 
received chemotherapy. For the purpose of this study, the 
time blocks were changed to 24 hours. The tool was 
adapted with permission of the author.
Form 2 was developed to measure the subject's 
perceived frequency of nausea, duration of nausea, 
distress from nausea, frequency of vomiting, amount of 
vomiting, distress from vomiting, frequency of dry heaves.
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and distress from dry heaves. The subject's total symptom 
experience score is obtained from the total score on the 
INV Form 2. In addition, there are several sub-scores 
that can be derived from the INV Form 2.
Rhodes et al. (1987) estimated concurrent validity 
of the INV Form 2 by comparing the ratings of patients 
with the ratings of a family member the evening after 
the patient received chemotherapy, using Spearman's 
correlation coefficient (r=.B7, n=18, p=.001).
Construct validity was measured by the tool's ability to 
discriminate between cancer patients and well citizens.
The Wilcoxon-Mann Whitney test was used for this purpose. 
Through factor analysis the three experience scales were 
supported as being distinct and unique.
After the completion of a study of nausea and 
vomiting using a previously constructed Index of Nausea 
and Vomiting Form 1 (INV Form 1) the INV Form 2 was 
developed. Internal reliability of the INV was measured 
by two methods. The split-half correlation was .90, and 
Cronbach's Alpha was .89 to .97 over 12 index 
administrations. These findings relate to the INV Form 1. 
No other information specific for Form 2 was given except 
Cronbach's Alpha, which was .98 (Rhodes et al., 1987).
The coefficient alpha for the twelve INV Form 2 items 
for this study was .93. The coefficient alpha for the
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nausea experience subscale was .92, .95 for the vomiting 
experience subscale, and .92 for the retching experience 
subscale.
Procedure
Application was made to the Grand Valley State 
University Human Research Review Committee for proposal 
approval. Approval was also obtained from the 
Research Committees of the hospitals in which subject 
recruitment took place. Once approval from all 
agencies was obtained, subject recruitment and data 
collection proceeded.
Recruitment of subjects occurred on the oncology 
units within three of the identified hospitals and via an 
oncology physician's office for patients admitted to the 
remaining hospital. An oncology nurse was contacted in 
three of the institutions and upon thorough discussion of 
the research data collection process, was recruited to 
collect data for the study. Each data collector was 
provided the appropriate tools, consent forms, and paper 
products required for data collection. Identification of 
subjects who met basic eligibility criteria occurred 
on a daily (Monday through Friday) basis at each 
institution. The researcher or nurse data collector 
reviewed admitting orders to confirm that the subject was
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indeed receiving cisplatin and was between cycle two and 
six of treatment.
Once eligible subjects had been identified, the 
researcher or nurse data collector made personal contact 
with each subject. The researcher or nurse data collector 
introduced herself, gave a brief statement regarding the 
nature of the research (Appendix F), and presented the 
subject with the appropriate consent form (Appendix G). 
Explanations were given at this time regarding the process 
for data collection. The researcher or nurse data 
collector then gave the subject time to read the 
consent form privately and then returned to the room to 
answer any questions and to pick up the consent form if 
it was signed. Once consent was obtained, one copy of the 
consent was placed in the subject's chart, one copy 
given to the subject, and the final copy retained by the 
researcher. At this time, the researcher or nurse data 
collector interviewed the subject, utilizing the 
demographic and related data form (Appendix A). The 
researcher or nurse data collector then completed the 
chart review form (Appendix B).
The patient questionnaire and the Health Related 
Hardiness Scale (Pollock, 1987) were mailed to the 
subjects approximately 10 days after the present 
chemotherapy treatment, requesting that they complete the
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forms and mail them back to the researcher (Appendix H). 
The intent was to have the subjects complete the 
questionnaires at a point in time when they had 
recovered optimally from the previous chemotherapy 
treatment and were not yet experiencing any distress in 
anticipation of the next treatment. Subjects were to 
complete the HRHS and the patient questionnaire within the 
privacy of their own home. Subjects were requested to 
mail the forms back to the researcher in a stamped, 
addressed envelope that was provided. To enhance 
confidentiality, the questionnaire was coded by number 
and the subjects were instructed not to identify 
themselves on any of the questionnaires completed during 
this study. If the forms were not received by the 
investigator within ten days of being mailed to the 
subject, a follow-up phone call was placed to the 
subj ect.
The INV Form 2 (Rhodes et al., 1987) was 
administered by the researcher or the nurse data collector 
the first day of the next admission to the hospital for 
chemotherapy, prior to pre-medications or chemotherapy 
being initiated. The subject was asked to complete the 
INV Form 2 at this time. The questionnaire was then 
placed in a plain envelope and returned to the researcher 
(Figure 2).
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Figure 2. Time Line of Interaction With Subjects
If requested at the time of informed consent, 
results of the study were mailed to the subject at 
the completion of the study. All consent forms and 
returned forms were kept in a locked file at the 
researcher's home to enhance confidentiality.
The chance of untoward effects resulting from this 
study were considered minimal, however, two potential 
risks were identified. First, it was possible that the 
subjects could become fatigued when completing the 40-item 
Health Related Hardiness Scale. The researcher attempted 
to reduce this risk by enabling the subjects to take this 
paper and pencil test in their own home, allowing the 
subjects to rest as needed.
Second, the study deals with the psychophysiological 
phenomenon of anticipatory nausea and vomiting. It was 
possible that through too much information being given to 
patients who have never experienced anticipatory nausea 
and vomiting, they were at an increased risk of developing 
anticipatory nausea and vomiting during their chemotherapy 
protocol. In an effort to reduce this threat, the 
researcher and nurse data collectors did not expose the 
subjects to the words "anticipatory nausea and vomiting". 
Finally, the tool utilized to measure this phenomenon 
was identified simply as a means to measure the subject's 
personal experience before chemotherapy.
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CHAPTER FOUR 
Data Analysis 
The life stress and illness model (Rahe, 1988) 
supports the relationship between stressor and symptom 
development in the cancer patient receiving chemotherapy. 
Anticipatory nausea and vomiting may be a 
psychophysiologic response to chemotherapy. The 
literature identifies the hardiness characteristic as a 
buffer, or resistance factor, in the stress/illness 
connection. Therefore, it is important to explore the 
relationship between hardiness and anticipatory nausea and 
vomiting in cancer patients.
The independent variable, the hardiness 
characteristic, including the concepts control, 
commitment, and challenge, were measured at the interval 
level for the total score. The dependent variable, 
anticipatory nausea and vomiting experienced by the 
patient receiving cisplatin chemotherapy, was also 
measured at the interval level. The Pearson r correlation 
coefficient was used to test the hypothesis: Individuals
with a high level of the hardiness characteristic 
(control, commitment, and challenge) will experience less
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anticipatory nausea and/or vomiting than those individuals 
with a low level of the hardiness characteristic. 
Relationships were considered to be significant at the 
0.05 level.
One other relationship explored by the study was the 
differences between males and females in relation to the 
hardiness characteristic in each group. The t-test was 
used to determine if the gender groups differed 
significantly in relation to the hardiness characteristic. 
All data were analyzed using the SPSS/PC package. 
Characteristics of Subjects
Identification of potential subjects for the study 
was made by the principal researcher and oncology nurse 
data collectors over a two year period within four 
institutions. More than one hundred patients were 
screened as potential candidates for the study, however, 
only forty subjects met the inclusion and exclusion 
criteria and consented to participate in the study. All 
forty candidates completed portions of the data collection 
process, with twenty-nine subjects completing all 
components of the data collection process. Nine subjects 
were unable to complete data collection as their treatment 
regime was changed prior to completing the final data 
collection tool, e.g., chemotherapy changed to radiation 
therapy or chemotherapy placed on hold. One subject was
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unable to complete the data collection instruments at home 
due to existing family dynamics which prevented him from 
receiving the mail. One subject expired as a result of 
his cancer just prior to readmission for chemotherapy, 
thus the final data collection tool was not completed.
The breakdown of subjects in the study according to 
study site is shown in Table 2.
Table 2.
Distribution of Sample Based on Data Collection Site
Site # of Subjects
529 bed regional hospital 29
190 bed community hospital 6
350 bed regional hospital 5
405 bed regional hospital 0
Twenty-four of the subjects were male and sixteen of 
the subjects were female. Age of the participants ranged 
from 36 to 79 years of age. The mean age was 56.87, with 
a standard deviation of 10.16. Thirty-two of the 
participants were married, four subjects were single, 
divorced, or widowed and living alone, and four subjects 
were single divorced, or widowed and living with someone. 
Thirty-nine subjects identified themselves as Caucasian, 
one subject as Hispanic. The distribution of subjects by 
ethnicity is listed in Table 3. The distribution of
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subjects by education is listed in Table 4. Demographic 
characteristics were similar with respect to marital 
status, race, and education. The majority of subjects 
were Caucasian and married with a high school or partial 
college education.
Table 3
Distribution of Sample by Ethnicity
Group
Characteristic Frequency Percent
Dutch 8 20.0
Irish 5 12.5
German 13 32.5
Polish 2 5.0
Scottish 2 5.0
Mexican 1 2.5
English 2 5.0
Lithuanian 1 2.5
Native American Indian 2 5.0
Other 2 5.0
None 2 5.0
Total 40 100.0
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Table 4.
Distribution of Sample by Education
Group
Characteristic Frequency Percent
Less than High School 6 15.0
High School 13 32.5
Partial College 14 35.0
College 4 10.0
Beyond 4 Years of College 3 7.5
Total 40 100.0
All 40 subjects had a confirmed diagnosis of cancer. 
Twenty subjects were diagnosed with lung cancer, while the 
remaining subjects had one of a variety of primary sites 
(Table 5). Twenty-six, or 65% of the sample had some 
metastatic disease present.
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Table 5
Distribution of Sample Based on Primary Site of Cancer
Primary Site
Group
Frequency Percent
Bladder 1 2.5
Testicle 4 10.0
Head/Neck 1 2.5
Lung 20 50.0
Breast 1 2.5
Bone 1 2.5
Uterine 2 5.0
Unknown 2 5.0
Other 7 17.5
N/A 1 2.5
Total 40 100.0
Point of entry into the study was after the 
completion of at least one course of chemotherapy and 
before receiving the fifth course of chemotherapy. 
Twenty-seven subjects were entered into the study prior to 
their second course of chemotherapy, eight subjects prior 
to their third course, four subjects prior to their fourth 
course, and one subject was entered prior to his fifth 
course of chemotherapy. The minimum dose of cisplatin the
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subject could receive for inclusion into the study was 
70 iag/m2. The distribution of the subjects based on 
cisplatin dose is listed on Table 6. Twenty-three 
subjects, or 57.5% of the sample received their cisplatin 
dose split and administered over more than one day, while 
the remaining 17 subjects, or 42.5% of the sample, 
received their cisplatin in a single dose. While 
cisplatin was identified as the primary chemotherapeutic 
agent the subjects were to receive, all forty subjects 
received at least one additional chemotherapeutic agent 
during their treatment regime.
Table 6
Distribution of Sample Based on Dose of Cisplatin
Dose Range
Group
Frequency Percent
7 0 - 7 9  mg/m2 17 42.5
80 - 89 mg/m2 8 20.0
9 0 - 9 9  mg/m2 6 15.0
100 - 109 mg/m2 8 20.0
> 120 mg/m2 1 2.5
Total 40 100.0
Fifteen of the subjects had someone close to 
them receive chemotherapy in the past. Seven of the
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individuals identified as being close to the subjects had 
experienced distressing symptoms while receiving 
chemotherapy, with nausea being the distressing symptom in 
four of the cases. Eight of the 40 subjects had 
themselves received chemotherapy treatments in the past 
(prior to the present regime), with six of those 
individuals having experienced distressing symptoms during 
that treatment regime. Nausea was identified as the most 
frequent distressing symptom in that group, experienced by 
three of the six subjects. Three subjects experienced 
nausea and/or vomiting prior to the initial chemotherapy 
treatment of the present treatment regime. Three subjects 
experienced mild distress from nausea in the two days 
prior to the chemotherapy treatment at which they were 
recruited into the study. No one experienced any vomiting 
in the two days prior to the chemotherapy treatment at 
which they were recruited into the study.
Table 7 identifies the distress from nausea 
experienced one week after the previous chemotherapy 
treatment as reported by the subjects. Table 8 
identifies the distress from vomiting experienced one week 
after the subject's previous chemotherapy treatment as 
reported by the subjects. It is evident that of those 
subjects experiencing nausea, mild nausea was most 
frequently experienced. Post-chemotherapy vomiting was
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experienced by fewer of the subjects than nausea, but was 
most often described as causing moderate distress. 
Pharmacological intervention to control post-chemotherapy 
nausea and vomiting was utilized by 77.9% of the subjects 
reporting this information (Table 9). Of the drugs 
identified, lorazepam (Ativan), prochlorperazine 
(Compazine), metoclopramide hydrochloride (Raglan), 
trimethobenzamide hydrochloride (Tigan), thiethylperazine 
maleate (Torecan), and ondansetron hydrochloride (Zofran), 
Torecan was taken by 50% of the subjects for control of 
post-chemotherapy nausea and vomiting.
Table 7
Distribution of Sample by Nausea Experienced One Week 
After Chemotherapy (n=36).
Characteristic
Group
Frequency Valid Percent
No nausea 11 30.6
Mild distress 13 36.1
Moderate distress 8 22.2
Severe distress 4 11.1
Total 36 100.0
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Table 8.
Distribution of Sample by Vomiting Experienced One Week 
After Chemotherapy (n=36).
Group
Characteristic Frequency Valid Percent
No yomiting 21 58.3
Mild vomiting 7 19.4
Moderate vomiting 8 22.2
Severe vomiting 0 0.0
Total 36 100.0
Table 9.
Distribution of Sample by Freauencv of Medication Taken
for Nausea & Vomiting One Week After Chemotherapy fn=36).
Group
Characteristic Frequency Valid Percent
No medication 8 22.2
2 X in 24 hours 15 41.7
3 - 4 X in 24 hours 11 30.6
> than 4 X in 24 hours 2 5.6
Total 36 100.0
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Thirty-nine of the forty subjects received Zofran 
prior to the administration of cisplatin, thirty received 
dexamethasone (Decadron), and seventeen received Ativan. 
Two subjects received furosemide (Lasix) as part of the 
pre-chemotherapy regime and one subj ect received 
diphenhydramine hydrochloride (Benadryl). All but two 
subjects received a combination of two or more drugs prior 
to the administration of cisplatin. The two subjects 
receiving only one drug prior to the administration of 
cisplatin received Zofran intravenously.
Thirty-six of the forty subjects were administered 
the Health Related Hardiness Scale (HRHS). Six returned 
HRHS forms had one or more missing items. Scores have the 
potential to range from 40-240, with low scores indicating 
hardiness. Hardiness is determined by using the median 
split of the sample, with those scores below the median 
indicating the presence of hardiness. Subscores for each 
of the concepts control, commitment, and challenge can be 
obtained from the HRHS. Control scores range from 14-84 
with low scores indicating high control, commitment scores 
range from 13-78, with low scores indicating high 
commitment, and challenge scores range from 13-78, with 
low scores indicating high challenge. The mean scores, 
median scores, and the standard deviations for the HRHS 
and the subscales are shown in Table 10. With a median
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score of below 90 representing hardiness, 14 subjects, or 
46.7% scored below the median score to indicate 
hardiness. Seventeen subjects, or 50.0% of the 34 
subjects completing the control subscale scored below the 
median score of 41.50 for the subscale indicating control. 
Twelve subjects, or 37.5% of the thirty-two subjects 
completing the commitment subscale scored below the median 
score of 23 indicating commitment. Sixteen, or 47.1% of 
the total thirty-four subjects completing the challenge 
subscale scored below the median score of 2 4 indicating a 
sense of challenge.
Table 10.
Mean Scores of the HRHS and Subscales
Score
Scale/Subscales M Median SD
HRHS Total (n=30) 87.833 90.00 14.518
Control (n=34) 41.971 41.50 9.622
Commitment (n=32) 23.375 23.00 6.729
Challenge (n=34) 25.618 24.00 6.325
Twenty-nine subjects were administered the Rhodes 
Index of Nausea and Vomiting Form 2 (INV Form 2). As this 
was the final data collection tool administered, eleven 
subjects were unable to complete this form (see page 36).
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Two forms had missing data when returned. The INV Form 2
has a potential range in scores from a low of 0 to a
maximum of 32. In addition, scores can be obtained 
from a variety of subscales. The subscales examined are 
those identified within the symptom experience subscale. 
They include the nausea experience with a potential range 
of scores of 0-12, the vomiting experience with a 
potential range of scores of 0-12, and the retching 
experience with a potential range of scores of 0-8. The 
mean score and standard deviations for the INV Form 2
total and selected subscales are shown on table 11. These
scores reflect very low levels of perceived anticipatory 
nausea, vomiting, or retching in the subject group as a 
whole.
Table 11
Mean Scores for the INV Form 2 and Selected Subscales
Score
Scale/Subscales M SD
INV Form 2 total (n=27) 1.667 3.637
Nausea experience (n=28) 1.179 2.144
Vomiting experience (n=29) .241 .912
Retching experience (n=28) .179 .670
45
Analysis of the Research Hypothesis
The Pearson r correlation coefficient was used to 
test the study hypothesis; Indiyiduals with a high leyel 
of the hardiness characteristic (control, commitment, and 
challenge) will experience less anticipatory nausea and/or 
yomiting than those indiyiduals with a low leyel of the 
hardiness characteristic. The Pearson r correlation 
coefficients were calculated to determine if a significant 
relationship existed between the total HRHS score with the 
total INV Form 2 score. Mean substitution with the 
yariable mean was used for those few items not answered by 
the participants. Results indicated no significant 
relationship between the total HRHS and the total INV 
Form 2 (r=.07, p=.72), thus the hypothesis was not 
supported.
A t-test was utilized to examine the differences 
between males and females in relation to the hardiness 
characteristic in each group. There was homogeneity of 
yariance so the pooled formula was used. There was no 
difference in the HRHS total based on gender (t=.77, 
dF=32, p=.445).
The Pearson r correlation coefficient was used to 
test each of the HRHS subscales (control, commitment, and 
challenge) to determine if a significant relationship 
existed between a subscale and the INV Form 2 score.
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Results indicated no significant relationship between any 
of the subscales and the INV Form 2 total (Table 12). 
Table 12
Correlations Between HRHS Subscales and INV Form 2 Totals
Subscales Coefficients Significance
Control .19 .35
Commitment -.19 .40
Challenge .10 .64
p=<.05
Additional Findings of Interest
Ethnicity and its relationship to hardiness was 
explored. A t-test was used to examine the differences 
between Dutch/German and Irish ethnic groups in relation 
to the HRHS total. These groups were chosen as they were 
the largest ethnic groups identified within the sample. 
There was no difference in the HRHS total based on 
ethnicity (t=.28, dF=4.38, p=.791).
A variety of relationships were examined related to 
the development of anticipatory nausea and vomiting. A t- 
test was used to examine the differences between subjects 
who had and those who had not received chemotherapy in the 
past in relation to the anticipatory nausea experience 
(subscale of the INV Form 2) with the present treatment 
protocol. There was no difference in the anticipatory
47
nausea experience based on past chemotherapy experience 
(t=-.44, dF=26, p=.665).
The anticipatory nausea and vomiting experience was 
also examined in relationship to subjects having had
someone close to them receive chemotherapy in the past. A
t-test was used to examine the differences between 
subjects who had someone and those who did not have
someone close to them receive chemotherapy in the past in
relation to the anticipatory nausea experience and the 
anticipatory vomiting experience with this chemotherapy 
regime. There was no difference in the anticipatory 
nausea experience based on having had someone close 
receive chemotherapy (t=1.02, dF=2 6, p=.318) nor in the 
anticipatory vomiting experience based on having had 
someone close receive chemotherapy (t=.63, dF=9.87, 
p=.544).
The Pearson r correlation coefficient was used to 
determine if a significant relationship existed between 
the amount of nausea one week after chemotherapy (from the 
previous course of cisplatin) with the amount of 
anticipatory nausea for the present course of 
chemotherapy. The Pearson r indicates there is some 
relationship approaching significance (r=.33, p=.07).
This same relationship was explored substituting vomiting
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for nausea, with the results indicating significance 
(r=.46, p=.01).
The dose of cisplatin and the method of administering 
the cisplatin (single dose or split doses) were analyzed 
in relationship to anticipatory nausea and vomiting. The 
Pearson r correlation coefficient was used to determine if 
a significant relationship existed between the dose of 
cisplatin administered and the anticipatory nausea 
experience. Results indicated no significant relationship 
between the dose of cisplatin and anticipatory nausea (r=- 
.05, p=.80). Similarly, there was no significant 
relationship between the dose of cisplatin and 
anticipatory vomiting (r=-.27, p=.14). A t-test was 
utilized to examine the differences between groups based 
on the dosing of cisplatin (single dose or split doses) 
and the amount of anticipatory nausea experienced by 
subjects. There was no significant difference between the 
single dose group and the split dose group and the amount 
of anticipatory nausea experienced (t=2.02, dF=13.21, 
p=.064).
Lastly, the Fisher's Exact test was used to analyze 
subjects who scored less than 90 on the HRHS (indicating 
hardiness) and subjects who scored 90 or greater on the 
HRHS with subjects who experienced no anticipatory nausea 
and vomiting and subjects who experienced some degree of
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anticipatory nausea and vomiting (based on INV Form 2 
totals). Table 13 demonstrates this relationship. 
Table 13
Relationship Between Presence of Hardiness and 
Anticipatory Nausea and Vomiting
Anticipatory Nausea and Vomiting 
No Yes
Hardy (n=13) 10 (77%) 3 (23%)
Not Hardy (n=14) 8 (57%) 6 (43%)
p=.249, one-tailed.
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CHAPTER FIVE 
Discussion and Implications
Discussion
This study was designed to examine the relationship 
between personality hardiness and the experience of 
anticipatory nausea and vomiting within a sample of 
patients receiving cisplatin as their primary 
chemotherapeutic agent. Kobasa (1979) identified 
hardiness as a buffer or resistance factor in the 
stress/illness connection. Recognizing that the symptoms 
of anticipatory nausea and vomiting may evolve via the 
process described in the life stress and illness model 
(Rahe, 1988), the results of this study were expected to 
support a correlation between hardiness and anticipatory 
nausea and vomiting. The data, however, did not support 
this premise. The findings of the study revealed no 
statistically significant relationship between hardiness 
and anticipatory nausea and vomiting. It is of clinical 
importance, however, that a much lower percentage of hardy 
individuals experienced anticipatory nausea and vomiting 
than the non hardy group.
The mean scores for the INV Form 2 and selected 
subscales (Table 11) indicate very low levels of perceived
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nausea, vomiting, or retching in the tventy-fcur hours 
prior to admission for chemotherapy. It was anticipated 
that there would be greater variability in the degree of 
these symptoms within the subject group as a whole. There 
may be a number of factors which influenced these low 
scores.
The literature (Pratt, Lazar, Penman, & Holland,
1984) supports the development of anticipatory nausea and 
vomiting based on the classical conditioning model, from 
which repeated experiences with an unconditioned stimulus 
(chemotherapy) contributes to an unconditioned reflexive 
response (post-chemotherapy nausea and vomiting). With 
repeated experiences, the conditioned response 
(anticipatory nausea and vomiting) may evolve. This model 
is supported by Morrow (1984) , identifying that paLicr.ts 
who experience moderate, severe, or intolerable nausea and 
vomiting post-chemotherapy were more likely to experience 
anticipatory nausea and vomiting. Data in this study 
found a relationship approaching significance between the 
amount of nausea one week after chemotherapy (from the 
previous course of cisplatin) with the amount of 
anticipatory nausea and vomiting for the present course of 
chemotherapy. Significance was achieved in examining this 
same relationship substituting vomiting for nausea. These 
findings support the literature, indicating post-
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chemotherapy nausea and vomiting influence the development 
of anticipatory nausea and vomiting.
Based on the classical conditioning model, it is 
logical that the further into the treatment protocol, the 
greater the potential would exist for anticipatory nausea 
and vomiting to develop. This is particularly true if the 
patient experiences distressing stimuli which act to 
elicit an unconditioned reflexive response. While the 
discussion above explains that the majority of subjects 
experienced no to mild levels of distress related to post­
chemotherapy nausea and vomiting, this may be due, in 
part, to the fact that 27 subjects were entered into the 
study prior to their second course of chemotherapy. The 
majority of subjects had few experiences with chemotherapy 
at this point, thus this may have contributed to the low 
INV Form 2 scores.
The introduction of ondansetron (Zofran), a serotonin 
antagonist, may also have influenced the INV Form 2 and 
subscale scores. Zofran was introduced to the clinical 
setting during the period of time the study was designed. 
Zofran has been widely utilized since that time as an 
antiemetic in pre-chemotherapy treatment regimes, as 
evidenced by the fact that 39 out of the 40 subjects in 
this study received this drug as a premedication for 
cisplatin. Clinical trials with this drug had promised
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new advances in the control of chemotherapy-induced nausea 
and vomiting (Egan, Taggart, & Bender, 1992). Control of 
nausea and vomiting during and immediately after 
chemotherapy will influence the development of 
anticipatory nausea and vomiting (Goodman, 1987). While 
no direct analysis of Zofran, post-chemotherapy nausea and 
vomiting, and anticipatory nausea and vomiting was carried 
out in this study, the low INV Form 2 and subscale scores 
may be a reflection of the effectiveness of this drug in 
controlling post-chemotherapy nausea and vomiting.
Additional factors thought to influence the 
development of anticipatory nausea and vomiting were 
examined. The theoretical framework for this study 
recognizes that many factors interface to produce an 
individual's perception and response to a stressor. 
Included in these factors are the life events an 
individual experiences. Experiences identified in the 
study which would be considered life events include having 
had someone close to the subject receive chemotherapy in 
the past and the subject himself having received 
chemotherapy prior to the current treatment regime.
There was no difference in the anticipatory nausea and 
vomiting experience based on either of these life events. 
This may be attributed to the fact that only 15 subjects 
had someone close to them receive chemotherapy and only
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in seven of these instances was the person perceived as 
having distressing symptoms as a result of the 
chemotherapy, of which nausea was the distressing symptom 
identified in four of the cases. Only eight of the 40 
subjects had received chemotherapy treatments previously, 
six of which experienced distressing symptoms, and three 
of these six had experienced nausea as the distressing 
symptom. It may be possible that other factors are 
impacting the perception of chemotherapy, both on an 
individual and societal level. Education has improved 
both on an individual level and family level for those 
undergoing chemotherapy treatments. Information has been 
widely disseminated within the public sector related to 
cancer, its treatment, potential side effects resulting 
from treatment, and the increasing frequency of positive 
outcomes once diagnosed with cancer. In addition,
survivorship and all that it implies has become the focus
of much of the information released to the health care 
team and public today. Based on this, the perception of 
cancer and its treatment may be slowly changing and may be
perceived in a less negative light.
The literature does not explore in detail factors that 
affect the development or presence of hardiness. In an 
effort to further explore this, two additional 
relationships were examined. The first relationship
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examined was that of hardiness and gender. The findings 
of this study indicated that there was no difference in 
the HRHS total score based on gender. Gender 
identification is influenced by biological aspects (e.g., 
anatomic and physiologic organs, hormones, etc.), 
psychologic aspects (e.g., sexual self-concept), and 
sociocultural aspects (e.g., gender role learned through 
family and society) (Hogan, 1985). It is plausible that 
these biopsychosocial factors may impact the development 
of hardiness, recognized in the literature as a 
personality characteristic, although this study did not 
support that relationship.
Lastly, ethnicity and its relationship to hardiness 
was explored. If factors can be identified that influence 
the development and presence of hardiness, ethnicity may 
be one of those factors. Subjects were asked to identify 
the ethnic group that they most closely identified with in 
their own lives. The Dutch and German groups were joined 
for analysis as they have somewhat similar cultural norms. 
The Dutch/German and Irish groups were chosen to examine 
the differences between them as they were the largest 
ethnic groups identified within the sample. The findings 
did not identify a difference in the HRHS total based on 
ethnicity.
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Limitations
As with many studies, there were identified threats 
to both internal and external validity. There were two 
major threats to internal validity identified in this 
study: maturation and testing effects. It was possible
for the subjects in this study to experience the effect of 
maturation as a result of their cancer disease process. 
Often fatigue and disease progression are unavoidable due 
in part to the chemotherapy treatment and the disease 
trajectory itself. Attempts were made to control this 
process by expediting the data collection process. Only a 
four week interval occurred between the initial contact 
and the final questionnaire.
The second risk to internal validity, testing 
effects, may have occurred as a result of the nature of 
the questionnaires. If the subjects were exposed to the 
questionnaire dealing with the hardiness characteristic 
prior to their next chemotherapy treatment, this may have 
stimulated the subjects to examine their own attitudes 
toward life and their diagnosis. This may, in turn, have 
affected their normal response to chemotherapy and altered 
the research findings. No mention of hardiness, control, 
commitment, or challenge was made directly to the 
subjects. They were told that this study was to examine 
how people view certain issues related to their own
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health. In addition, the questionnaires were administered 
at one point between cycle two and six of the individual's 
chemotherapy protocol, thus the pattern of anticipatory 
nausea and vomiting would likely be already established.
The two major threats to generalizability were 
identified as experimenter effects and characteristics of 
the sample. The performance of the subjects may have been 
affected by the researcher's expectations. The subjects 
may have recognized the researcher's interest and 
enthusiasm for the project, and answered the 
questionnaires in the manner they think the researcher or 
nurse data collectors expected them to be answered. An 
attempt was made to reduce this threat by the presentation 
of a brief, simple introductory statement made to each 
subject (Appendix F).
The small sample size was a limitation to the study. 
The subjects were fairly homogenous as a group with the 
majority being married, Caucasian with a high school or 
partial college education. Another limitation was that 
convenience sampling was utilized for the study. Almost 
every patient receiving cisplatin during the study period 
was reviewed as a potential subject for the study, 
excluding only those who did not meet the inclusion and 
exclusion criteria. Despite this, data collection took 
two years with four data collectors in four different
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institutions. This was attributed, in part, to the fact 
that cancer therapy advances, making other 
chemotherapeutic drugs available to patients, occurred 
during the time frame this study was conducted. Several 
subjects consented to participate in the study, but were 
unable to complete all aspects of the data collection 
process as a result of a change in therapy. One subject 
expired as a result of his cancer prior to completing the 
data collection process. As a result of this method of 
sampling, the findings cannot be generalized to the total 
cancer population.
Another factor that may have influenced the results 
of this study was the introduction of Zofran as an 
antiemetic. This drug has been identified in the 
literature and by cancer clinicians as effectively 
reducing the amount of post-chemotherapy nausea and 
vomiting. The effect of this drug on the study results is 
unknown, but may have impacted the levels of anticipatory 
nausea and vomiting experienced by the subjects.
The Health Related Hardiness Scale used in this study 
must be examined as a potential limitation related to the 
results of this study. The reliability coefficients for 
the challenge subscale (.26) and the commitment subscale 
(.48) indicate a low degree of internal consistency within 
these scales. Wagnild and Young (1991) examined a number
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of concerns in relationship to the instruments presently 
being used to measure hardiness. Their review of the 
literature revealed that a number of studies have 
identified the challenge subscale as being problematic and 
lacking internal consistency. Hull, Van Treuren, and 
Virnelli (1987) also examined hardiness and its 
subcomponents, identifying that only commitment and 
control have adequate psychometric properties (based on 
the Hardiness Scale developed by Kobasa) and are 
systematically related to health outcomes. Hull, Van 
Treuren, and Virnelli recommend that composite hardiness 
should not be calculated because this does not allow for 
the independent contributions of each subcomponent 
(challenge, commitment, and control). Pollock and Duffey 
(1990) describe the development and the psychometric 
evaluation of the present HRHS scale, which has evolved to 
a 34-item instrument. The conclusion of the authors is 
that two separate but related dimensions exist, those of 
commitment/challenge and control. The recommendation is 
that a total HRHS score and the two subscores be obtained 
from this newer instrument.
At the time this study was designed, the 40-item HRHS 
was the current instrument to measure hardiness and the 
subcomponents control, challenge, commitment. Further 
analysis of the instrument has identified problems with
60
measuring the three subcomponents individually. Based on 
the variety of instruments available to measure hardiness 
and the questions that remain related to the consistency 
of the subscales, further research and testing of the 
instruments is indicated.
The data collection tool used to elicit information 
related to post-chemotherapy nausea and vomiting (Appendix 
C) was also a limitation to the study. This tool was 
designed as a self-reporting tool. It was completed by 
the subjects approximately two weeks after the previous 
chemotherapy treatment, thus the subject's perceived 
experiences at that point in time may have differed from 
their actual experiences at the time they were having 
post-chemotherapy nausea and vomiting. The tool is 
designed poorly in regard that the responses allow room 
for individual interpretation. The responses include 
choices such as no nausea, mild distress from nausea, 
moderate distress from nausea, etc. Each individual may 
interpret these responses differently based on their own 
sense of what mild, moderate, and severe indicate. 
Implications for Nursing Practice
While the hypothesis was not supported there remain 
important implications for nursing practice. Given the 
fact that a much lower percentage of hardy individuals 
experienced anticipatory nausea and vomiting when compared
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to non hardy individuals, recognition of hardiness in the 
clinical setting is important. Nursing interventions that 
may impact an individual’s ability to maximize 
characteristics such as hardiness in a stressful situation 
may be as simple as giving the patient control over his 
environment whenever possible. These may be basic 
interventions such as mutually establishing appropriate 
medication schedules according to the patient's needs and 
desires, empowering the patient to control environmental 
stimuli such as noise, television, lights, and routines, 
and advocating for the patient who chooses to use 
interventions such as imagery and music therapy. There 
are undeniably many factors that impact the complexity 
with which an individual responds to illness and the 
treatment regime, however, hardiness may be an important 
characteristic that may promote a positive response in the 
patient facing stress and illness.
Cancer patients continue to provide a myriad of 
challenges for nursing practitioners, particularly in 
relationship to the side effects to chemotherapy. This 
study does support, albeit weakly, the relationship of 
post-chemotherapy nausea and vomiting to anticipatory 
nausea and vomiting. While the scores of the INV Form 2 
would indicate low levels of anticipatory nausea and 
vomiting, it is important to control post-chemotherapy
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nausea and vomiting. Clearly Zofran may impact this, but 
it remains an important nursing challenge to provide 
nursing care to combat the side effects of chemotherapy. 
Such interventions may focus not only from a 
pharmacological basis, but also from a behavioral basis. 
These patients may benefit from interventions such as 
imagery, music therapy, and relaxation breathing 
techniques.
Recommendations for Future Research
Although the hypothesis was not supported 
statistically, the fact that hardy individuals experienced 
anticipatory nausea and vomiting in much lower percentages 
would suggest a continued exploration with refined 
instruments, additional variables and larger samples.
Based upon the changes encountered with cancer treatment 
and symptom control since the inception of this study, 
replication of this study would not be advised. However, 
as hardiness is considered a personality characteristic, 
it could be examined in relationship to any health care 
issue experienced by an individual. This may include 
symptom development, perceived symptom experience, 
response to illness, impact on health promotion behaviors, 
etc.
Hardiness should be explored not only in relationship 
to health care issues, but in relationship to the
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characteristic itself. Of particular interest would be 
how this characteristic develops or evolves within the 
individual. If this were determined, recommendations 
could be made for interventions to promote or develop the 
characteristic within the individual or to enhance the 
buffering effects of this characteristic in times of 
stress or illness.
Another potential source for further research was 
identified during the selection process of subjects for 
this study. Many of the potential subjects were not 
receiving high dose cisplatin (>70mg/m2). In one 
location, fourteen potential subject charts were reviewed 
with not one patient receiving high dose cisplatin, 
despite the fact that the diagnosis may have indicated 
this treatment regime was appropriate. It is not the 
intent of this study to determine appropriate medical 
practice and this study did not examine the different 
drugs used in conjunction with cisplatin, which may impact 
the dose of cisplatin administered. As a result of this 
incidental finding, however, it may be of interest to 
research factors influencing the dosing of cisplatin in 
the various cancer patient populations and the 
geographical locale of these patients.
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Conclusion
The purpose of this study was to determine the 
relationship between hardiness and the amount of 
anticipatory nausea and vomiting in patients receiving 
cisplatin chemotherapy. The investigator concluded that 
there was no statistically significant relationship 
between the independent variable hardiness and the 
dependent variable anticipatory nausea and vomiting. 
However, small sample size was a major limitation to this 
study. Hardiness may well impact the individual's ability 
to buffer stress and symptom development when confronted 
with an illness, but further research must be conducted to 
explore this relationship in more depth.
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APPENDICES
APPENDIX A
Demographic and Related Data 
Please answer each question as accurately as possible.
1. Age;___________ years (to the nearest year) .
2. Gender: 1 male 2 female
3. Marital status:
 1___ Married
 2___ Single/divorced/widowed, living alone
 3___ Single/divorced/widowed, living with someone
you are close to
4. Race :
 1___ Caucas ian
 2___ Black
 3___ Hispanic
 4___ Asian
 5___ Native American
 6___ Other (please identify)_______________________
5. Highest level of education completed;
 1___ Less than high school
 2___ High school
 3 Partial college education (3 years or less)
 4___ College education (4 years)
 5___ Beyond 4 years of college
6. Which ethnic group do you identify with?
7. Has any one close to you ever received chemotherapy 
for the treatment of cancer?
 1___ Yes
2 No
6 6
8. If answered "yes" to item 7:
Did this person experience any distressing symptoms 
during their chemotherapy?
 1___ Yes
 2___ No
9. If answered "yes" to item 8:
What were the distressing symptoms that person 
experienced?
 1___ Anorexia
 2___ Nausea
 3___ Vomiting
 4___ Hair loss
 5___ Weakness/fatigue
 6___ Stomatitis
 7___ Pain at injection site
 8___ Bruising
 9___ Bleeding
10 Others
10. Have you had any past chemotherapy treatments 
(prior to this course of therapy)?
 1___ Yes
 2___ No
11. If answered "yes" to item 10:
Did you experience any distressing symptoms during 
that chemotherapy treatment regime?
 1___ Yes
 2___ No
12. If answered "yes" to item 11:
What distressing symptoms did you experience during 
that chemotherapy regime?
 1___ Anorexia
 2___ Nausea
 3___Vomiting
 4___Hair loss
 5___Weakness/fatigue
 6___Stomatitis
 7___Pain at injection site
 8___Bruising
 9___Bleeding
10 Others
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13. With the present chemotherapy treatments you are 
undergoing, did you experience any nausea and 
vomiting before the very first treatment?
 1___ Yes
 2___ No
14. With the present chemotherapy treatments you are 
undergoing, how much nausea do you experience in the 
two days before coming in for treatment?
 1___ I do not experience any nausea.
 2___ I experience only mild distress from nausea.
 3___ I experience moderate distress from nausea.
 4___I experience severe distress from nausea.
15. With the present chemotherapy treatments you are 
undergoing, how much vomiting do you experience in 
the two days before coming in for treatment?
 1___I do not experience any vomiting.
 2___I experience only mild distress from vomiting.
 3___I experience moderate distress from vomiting.
 4___I experience severe distress from vomiting.
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APPENDIX B
Chart Review Form
1. Cycle number of chemotherapy this admission;
 1___ Cycle two
 2___ Cycle three
 3___ Cycle four
 4___ Cycle five
2. Dose of cisplatin to be received this cycle of 
chemotherapy:
 1___ 70-79 mg/m2
 2___ 80-89 mg/m2
 3___ 90-99 mg/m2
 4____100-109 mg/m2
 5___ > 110 mg/m2
3. Drug protocol for the administration of cisplatin this 
chemotherapy cycle:
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4. Drug protocols for the administration of cisplatin 
the previous chemotherapy cycles:
Cycle 1: Date:
Cycle 2: Date:
Cycle 3: Date;
Cycle 4: Date:
Primary site of cancer:
 1___ Bladder
 2___ Testicle
 3___ Ovary
 4___ Head/Neck
 5___ Cervix
 6___ Lung
 7___ Breast
8 Other
6. Is metastatic disease present?
 1 Yes
 2 No
7. If item "6" is Yes, identify area/s of metastatic 
disease:
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APPENDIX C
Patient Questionnaire 
Please answer each question as accurately as possible.
1. How much nausea did you experience during the first 
week after your last chemotherapy treatment?
 1___ I did not experience any nausea.
 2___ I experienced only mild distress from nausea.
 3___ I experienced moderate distress from nausea.
 4___ I experienced severe distress from nausea.
2. How much vomiting did you experience during the first 
week after your last chemotherapy treatment?
 1___I did not experience any vomiting.
 2___I experienced only mild distress from vomiting.
 3___I experienced moderate distress from vomiting.
 4___I experienced severe distress from vomiting.
3. Did you take any medication to prevent or control 
nausea and vomiting the first week after your last 
chemotherapy treatment?
 1___ I did not take any medication to prevent or
control nausea and vomiting.
 2___ I took medication to prevent or control nausea
and vomiting one to two times in a twenty-four 
hour period.
 3___ I took medication to prevent or control nausea
and vomiting three to four times in a twenty-four 
hour period.
 4___ I took medication to prevent or control nausea
and vomiting more than four times in a twenty- 
four hour period.
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If you took medication to prevent or control nausea 
and vomiting after your last chemotherapy, please 
complete the following information;
1 Name of medication:____ ____
2 Dose of medication if known:
3 How often you took the medication:
YOU HAVE COMPLETED THIS QUESTIONNAIRE. PLEASE CHECK AND 
MAKE SURE YOU HAVE ANSWERED ALL THE QUESTIONS 
THAT APPLY TO YOU.
THANK YOU!1 ! !
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APPENDIX D
Health Related Hardiness Scale
Number
IIF.AI.TIl RI'.bATEh IIARDINESS SCALE
Iiistruclions:
Til!*: is n qucsliotinnirc designed lo determine llie wny in vvliicli different people view 
ccrtnin iinportnnt issues related to their Iienlth. Each item is n belief stntemcnt with 
which you mny ngree or disagree. Beside each statement is a scale which ranges from 
strongly disagree (1) to strongly ngreo (G).‘~Tdr each item wo would like you to circle the 
number that represents the extent to which you disagree or agree with the statement. 
Please moke sure that you answer every Item and that you circle only one number per 
item.
DISAGREE AGREE
s M S S M S
T 0 L h 0 T
R D 1 1 D R
.0 E G G E 0
N R 11 n R N
G A T T A G
L T L L T L
Y E Y Y E Y
L 1,
y Y
1 2 3 4 5 6 ___ 1. When l get sick 1 am to blame.
1 2 3 4 5 G ___ 2. 1 can avoid illness, if I take care of myself.
1 2 3 4 5 G ___ 3. I find it difficult to imagine enthusiasm about good
health.
1 2 3 4 5 G ___ 4. Luck ploys a big port in determining how soon 1
will recover from an Illness.
I 2 3 4 5 G ___ S. No matter how hard 1 try to maintain my henllh,
my efforts will accomplish very little.
I 2 3 4 S G ___ G. I am in control of my health.
I 2 3 4 5 fi __ 7. 1 admire people who work hard to Improve their
health.
1 2 3 4 5 G ___ 8. .It is more important lo hnve financial security
than good health.
1 2 3 4 5 G ___ 9. The ideas about health promotion and illness
prevention are social inventions to limit freedom
of action.
1 2 3 4 5 6 __ 10. My good health is largely a matter of good
fortune.
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IJISAGaC!’. AGREE
Number
M S • S M S
O I, E O •r
IJ I I 1) It
F. G G E o
U I I It N
A T r A G
T E E T E
E Y Y E Y
t. E
Y Y
2 , 3 <1 5 G ___ It. No matter wlint I do, I’m likely lo pet sick.
2 3 4 5 G ___ 12. 1 find it boring to cat and exercise properly to
maintain iny licallli.
2 3 4 5 G 13. The main thing which affodts my health is what I
myself do.
2 3 4 5 G ___ 14. Changes taking place In health care are not
exciting to me.
2 3 4 5 G ___ 15. I find people who are Involved In health promotion
interesting.
2 3 4 5 G ___■ IG. Setting goals for health is unrealistic.
2 - 4 5 G ___ 17. Most things that affect my health happen to me by
accident.
2 3 4 5 G ___ 18. Close relationships with others contribute to my
mental and physical well-being.
2 3 4 5 G ___ 19. Changes taking place In health care will have no
effect on me.
2 3 4 5 G ___ 20. If 1 get sick. It is my own behavior which
determines how soon 1 get well again.
2 3 4 5 G 21. I do not find It interesting to learn about health.
2 3 4 5 G ___ 22. 1 will stay healthy If It's meant to be.
2 3 4 5 G ___ 23. 1 am not Interested In exploring new health care
regimens or programs to Improve my health.
2 3 4 5 G ___ 24. A close relationship with my family has no effect
on my health.
2 3 4 5 G 25. The only reason to be Involved In the health
promotion movement Is to Inercnse my lifespan.
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UISACItr.K ACIII'.F.
Niiintjcr
s M •S • S M S
1 O L 1, O T
It U 1 1 0 R
0 r. G G E O
M Il II I R N
G A r T A G
1. T 1. h 1 1.
Y F. Y Y F. Y
h L
Y Y
1 2 3 4 5 G
2
2
2
2
2
2
2
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
S
5
5
5
5
2 3 4 5
2 3 4 5
6
G
6
G
6
G
G
2G. No>nnllcr wlial I do, if I am going lo get sick, t 
win get sick.
27. 1 feel no need to try to mnintnin my licallli, 
because it makes no difference anyway.
28. Tlie current focus on licniUli promotion is a fad 
tlinl will probably disappear.
29. No matter how hard I work to promote health for 
society. It never seems to improve.
30. Our society holds no worthwhile goals or values 
about health.
31. If I take the right actions, I can stay healthy.
32. 1 get excited about the possibility of Improving my 
health.
33. I am determined to be as healthy as I can be.
34. When my health Is threatened, I view it as a
challenge that must be overcome.
35. I read everything I can about health.
3G. 1 can be as healthy os I want to be.
37. I see nothing wrong with taking risks with my 
health.
38. When something goes wrong with my health, 1 do 
everything I can to get at the root of the problem.
39. I have little influence over my health.
40. Adequate rest Is part of my daily routine.
*• Copyright 1988, Susan F.. Pollock, Ph.D.
YOU HAVE COMPLETED THIS QUESTIONNAIRE. PLEASE CHECK AND 
MAKE SURE YOU HAVE ANSWERED ALL QUESTIONS.
THANK YOU! ! ! !
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RHODES INV-FORM 2
Directions: Draw a  circle around or mark through the sen ten ce  in each  row that m ost
clearly corresponds to your experience. P lease  m ake one mark on each line.
I D. N um ber. 
T im e_______
D a t e .
Time ol C T,
5ven or more 
tir the last
12 hours. '
I threw up five-six times 
during the last 12 hours.
I threw up three-four times 
during the last 12 hours.
I threw up one-two times 
during the last 12 hours.
did n o ,^ h f6 w  up during  
1 2  h o u rs .
During the last 12 
I have not felt any distreBi 
from retching or dry h eaves.
During the last 12 hours I 
have felt a s  sev ere  d istress  
from vomiting a s  can be.
I have not felt n au seated  
or sick at my stom ach  
during the last 12 hours.
During the last 12 hours I 
have not felt any d istress  
from nau sea /sick n ess at my 
stom ach.
During the last 12 hours, I 
produced a  very large  (3 
cups or more) am ount each  
time 1 threw up.
I have felt n au seated  or s 
at my stom ach seven /d r  
more different tim ^g^uring  
the last 12 houîs
During thp/fast 12 hours 
I ha\iej)fad  NO periods of 
retcljiffg or dry h ea v es  with- 
opt^ringing anything up.
During the last 12 hours, 
have felt mild distress 
retching or dry heaves.
During the la s K 2  hours 
have felt great distress 
from vomiting.
I have felt nauseated or sick 
at my stom ach for one hour 
or le s s  during the last 12 
hours.
During the last 12 hour^  
have felt mild d istre^  
from n a u sea  or sigkfiess at 
my stom ach.
During 12 hours, I
produeiM a large  (2-3 cups) 
arndunt each  time I threw
I h ave felt nauseated  or sick 
at my stom ach five-six dif­
ferent tim es during the last 
12 hours.
During the last 12 hours I 
have had 1-2 periods of 
retching or dry h eaves with­
out bringing anything up.
During the last 12 hours 
I have felt m oderate 
distress from retching or 
dry h ea v es.
During the last 12 hours I 
have felt m oderate d istce^  
from vomiting.
^ e  fell 
atrn^ s^  
of t h a ^
se a te d  or sick 
lach for two-three 
12 hours.
During the last 12 h ^ r s  
have felt m oderate distress 
from n au sea  or sick n ess ; 
my stom ach.
During the last 12 hours, I 
produced a m oderate (%-2 
cups) amount each  time I 
threw up.
I have felt nauseated  or sick  
at my stom ach three-four 
different tim es during the 
last 12 hours.
During the last 12 hours I 
have had 3-4 periods of 
retching or dry h ea v es  with­
out bringing anything up.
During the last Ig^tTurs, i 
have felt (
from retctjirtg’or dry heaves.
During the last 12 hours 
I have felt mild distress  
from vomiting
I have felt nauseated  or sick  
at my stom ach four to six 
of the last 12 hours.
During the last 12 hours I 
have felt great d istress  
from n au sea  or sick n ess at 
ny stom ach.
D urirtg^ e last 12 hours, I 
producebka sm a// (up to 
'/2  cup) arnbypt each  time I 
threw up.
I have felt nauseated^b^sick  
at my stom ach one-twoS  
ferent tim es during the last  
12 hours.
During the last 12 hours I 
have had 5-6 periods of 
retching or dry h ea v es  with­
out bringing anything up.
Copyright 1983. Curators of tvtissouri.
During the last 12 hours 
I have felt a s  severe  
distress from retching or 
dry h ea v es  a s  can be.
During the last 12 hours I 
have not felt any distress 
from vomiting.
I have felt nauseated  or sick 
at my stom ach more than 
six of the last 12 hours.
During the last 12 hours I 
have felt a s  severe  distress 
from n au sea  or s ick n ess at 
my stom ach a s  can be.
During the last 12 hours, I 
did not throw up.
I have not felt nauseated  or 
sick at my stom ach during 
the last 12 hours.
D uringSi^  last 12 hours I 
have hao% or more periods 
of retching oN(Jry h eaves  
without bringing êüîjrihing up.
Verna A. R hodes, RN,
Instructions for administering and scoring may be obtained from V. 
University of Missouri, Columbia, MO 65211; 314-882-0204.
Rhodes or J. Lay, S221 School of Nursing Building,
INV SCALE
C om p lete  one  INV S c a le  starting 
at 7, 8, o r 9  p .m . th e  even in g  
follow ing ch em oth erap y
C h o o se  th e  b e s t  hour for your 
sch ed u le .
B eginn ing with your ch o sen  hour, 
co m p iete  o n e  INV S c a le  every 12  
hours at th e  sam e  c lock  hour for 
six  tim es.
E xam ple: 7  PM - 7  AM
8  PM - 8  AM
9  PM - 9  AM
VR:lb
7 /2 1 /8 2
APPENDIX F
Introductory Statement
Hello, I am Colleen Smith, a registered nurse. I 
am conducting a study to find out what people think 
about their health and how they feel before getting 
their chemotherapy treatments.
I hope that information gained from this study will 
help nurses and doctors to better meet the needs of 
cancer patients. In order to conduct my study, I need 
several patients to answer a few questions and complete 
three brief paper and pencil questionnaires. Two of the 
questionnaires will be mailed to you to be completed in 
your home. These questionnaires will require about 20-30 
minutes to complete. The other questionnaire will be 
given to you at the time of your next admission for 
chemotherapy. This questionnaire will require about 5 
minutes to complete.
Please understand that at no time will you be 
identified and that all information is kept strictly 
confidential.
If you are interested in participating, I would like 
to leave this consent form for you to read and sign. I 
will return in a few minutes to pick up the form. Your
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signature on the consent form will indicate your consent 
to participate in this study, at which time you will 
receive further information and instructions.
Thank you very much for your cooperation.
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APPENDIX G
Consent to Participate in Study
I am aware that this is a study of how people view certain 
important issues related to their health. I also 
understand that this study will examine how I feel just 
before and after I receive my chemotherapy treatment. I 
understand that the knowledge gained is expected to help 
nurses and physicians provide health care in a manner 
which will be responsive to the needs of patients 
receiving chemotherapy.
I also understand that:
1. participation in this study will involve a 
brief interview that will be conducted after
I sign the consent form. Participation will also 
include three paper and pencil questionnaires to 
be completed one time only. The first 
questionnaire will deal with general information 
about how I feel after my chemotherapy. The 
second questionnaire will deal with how I view 
certain issues related to my health. Both of 
these questionnaires will be mailed to me so I 
can complete them in my own home. The third 
questionnaire will deal with how I feel just 
before I receive my chemotherapy. This 
questionnaire will be given to me to complete in 
the hospital the day I am admitted to receive my 
next chemotherapy treatment.
2. there are no anticipated physical or emotional 
risks as a result of participating in this study.
3. a summary of the results will be made available 
to me upon my request.
I acknowledge that:
I have been given an opportunity to ask questions 
regarding this research study, and that these 
questions have been answered to my satisfaction.
In giving my consent, I understand that my 
participation in this study is voluntary and that I 
may withdraw at any time without affecting the care I 
receive from my physicians or the staff at 
Butterworth Hospital.
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I understand I will receive no payment for my 
participation. Continuing medical care and/or 
hospitalization will not be provided free of charge, 
nor will financial compensation be available.
The investigator and/or delegated representatives 
from Butterworth Hospital and/or the Food and Drug 
Administration may inspect any data collected in 
relationship to this study where appropriate and 
necessary.
The investigator, Colleen Smith, has my permission to 
review my chart regarding my chemotherapy drugs and 
dosage.
I hereby authorize the investigator to release the 
information obtained in this study to scientific 
literature. I understand that I will not be 
identified by name.
I may contact Colleen Smith at (616) 732-3541 between 
9AM and 5PM Monday through Friday for any questions. 
Should I have any questions regarding my rights as a 
patient, I may call the Human Rights Committee 
Representative at 774-1299.
I acknowledge that I have read and understand the above 
information, and that I agree to participate in this 
study.
(Witness) (Participant Signature)
(Date) (Date)
(Investigator Signature)
(Date)
_I am interested in receiving a summary of the study 
results.
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APPENDIX H
Cover Letter
Date
Subject Name_ 
Address
Dear
As you recall, you agreed to participate in my research 
study while you were at Butterworth Hospital. As a part 
of this study, I am asking you to fill out the two 
questionnaires which are enclosed. They should require 
about 20-3 0 minutes to complete. A stamped, addressed 
envelope is provided for you to return the completed 
questionnaires to me. Do not sign your name or identify 
yourself in any way on the questionnaires. Please 
complete and return them at your earliest convenience.
Also enclosed find a stamped, addressed postcard which 
requests information about your next admission for 
treatment. Please complete this postcard and drop it in 
the mail when you are able to determine the date of your 
next admission. This information will enable me to 
provide you with the final questionnaire for the study at 
the time of your next admission. This questionnaire will 
be brief, requiring only about 5 minutes to complete. 
Please mail the postcard separate from the questionnaires 
you have completed.
I look forward to receiving your completed questionnaires 
and postcard soon and to seeing you again in the next few 
weeks.
Sincerely,
Colleen Smith, RN, BSN
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